Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

OBJECTIVES: Non-small cell lung cancer (NSCLC) accounts for 75–85% of all lung cancer diagnoses. This meta-analysis sought to estimate the overall survival (OS) of NSCLC based on randomized control trials which had compared docetaxel with kinase inhibitors, antineoplastic agents, and monoclonal anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagaraju, Chaitra, Vaidya, Gayatri, Jain, Anisha S., Nair, Amrutha Puthiyidath, Chandrappa, Sahana, Srinivasa, Chandrashekar, Suresh, Kuralayanapalya Puttahonnappa, Patil, Sharanagouda S., Shivananda, Bindya, Kollur, Shiva Prasad, Shivamallu, Chandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OMJ 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618033/
https://www.ncbi.nlm.nih.gov/pubmed/36341003
http://dx.doi.org/10.5001/omj.2022.86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618033/
https://www.ncbi.nlm.nih.gov/pubmed/36341003
http://dx.doi.org/10.5001/omj.2022.86

Ejemplares similares